That's what makes us unique.Why Pharmatech AI?
We own & use our620k m² Research Center
Our Center features 60 hectares (120K m² indoor), energy-independent with 55 MWp solar (55 GWh/year), CO2-positive, and scalable enabling sustainable, large-scale industrial hemp production.
We develop & offer anUnique AI Model 'AI-MDIP'
We develop an advanced GNN-Transformer AI predicting 250K–5M molecular interactions including 50K cannabis-specific compounds for precision drug discovery and bioactive optimization.
We own & use ourMDIP Practical Laboratory
Our 200 m² AI-powered Cannabis Lab (2025) generates 15K data points per cycle with full seed-to-flower data control ensuring reproducible precision breeding and advanced analytics.
Accelerating the Pharma Revolution
AI-Powered Drug Discovery
Pharmatech AI leverages AI-MDIP to revolutionize drug discovery, targeting a $137B drug discovery market with non-opioid pain solutions, high-growth cannabinoid therapies, and nanomedicine, backed by a 60-hectare campus and proprietary data for $500M-$1B exit potential.
Built with Leading Scientific AI FrameworksPowered by Cutting-Edge Research Technologies
Our AI platform combines powerful open-source technologies: PyTorch Geometric for graph-based drug discovery, DeepChem for molecular modeling, RDKit for cheminformatics, Deep Graph Library (DGL) for neural networks, and scikit-learn for machine learning. PyTorch and the PyTorch logo are trademarks of Facebook, Inc. Other logos are property of their respective owners.
“Drug discovery is like deciphering a secret language whose alphabet changes with every letter.”
Ercan Hayvali, M.Sc., Founder
Access Pharma's Billion-Dollar MarketIntroducing the $PCH Token
PCH Token Ecosystem
The PCH token, a high-growth utility token, offers investors a unique entry into the billion-dollar pharmaceutical market through Pharmatech AI’s innovative AI-driven platform.
We monetize cutting-edge research and our AI platform via lucrative pharma licenses, subscriptions, and a data marketplace, with stakers sharing 70% of profits, targeting $84M annually by 2028. Built on the BEP20 standard with a fixed 1B token supply, PCH empowers investors to stake for stablecoin profit sharing, engage in governance, and benefit from deflationary value growth through a buy-back-and-burn mechanism. Exclusive features like licensing auctions and community incentives ensure investors thrive in the booming pharmaceutical sector.
TOTAL SUPPLY
01234567890 B
fixed PCH token supply, ensuring scarcity & long-term value potential.
STAKING REWARDS
$0123456789001234567890 M
projected annual revenue share for stakers by 2028, paid quarterly in stablecoins.
“The science is clear that marijuana is a valuable medicine and should be treated as such with sensible legislation supporting its research and use.”
Sanjay Gupta, American Neurosurgeon
Frequently Asked Questions FAQ
This FAQ addresses key questions to highlight the project's potential and benefits.
What is Pharmatech AI and their Mission?
Pharmatech AI is a company using artificial intelligence to transform how new drugs are discovered, especially in areas like pain relief and cannabinoid research. Their goal is to speed up and lower the cost of developing new drug combinations, making healthcare innovation more accessible.
What Technology Makes them Special?
They will develop the AI Multi-Drug Interaction Predictor (AI-MDIP), a high-tech AI model that predicts how different drugs interact, including cannabis compounds, using advanced methods like Graph Neural Networks. They also grow cannabis in their own lab to create unique data, giving them an edge over competitors.
How Does the PCH Token Work?
The PCH token, with a fixed supply of 1 billion, is used within their ecosystem for bidding on drug licenses, staking to earn revenue shares in stablecoins, voting on project decisions, and getting community rewards. A buy-back-and-burn strategy reduces the token supply, potentially increasing its value over time.
What’s the Market Potential?
The markets they target are huge and expanding: the global drug discovery market is expected to reach $137.72 billion by 2029, AI in drug discovery $7.1 billion by 2030, and medical cannabis $41.4 billion by 2030. They plan to earn $150-300 million from licensing by 2027 and $25 million yearly from subscriptions by 2028.
How Can Investors Benefit?
By holding PCH tokens, investors can stake them to receive 70% of platform revenues quarterly in stablecoins, see potential value growth from the buy-back-and-burn, and use tokens for ecosystem activities. They can also influence project decisions through governance, aligning their investment with Pharmatech AI’s success.
